Articles: low-back-pain.
-
Bmc Musculoskel Dis · Nov 2020
World Health Organisation Disability Assessment Schedule (WHODAS 2.0): development and validation of the Nigerian Igbo version in patients with chronic low back pain.
Globally, the leading cause of years lived with disability is low back pain (LBP). Chronic low back pain (CLBP) is responsible for most of the cost and disability associated with LBP. This is more devastating in low income countries, particularly in rural Nigeria with one of the greatest global burdens of LBP. No Igbo back pain specific measure captures remunerative or non-remunerative work outcomes. Disability measurement using these tools may not fully explain work-related disability and community participation, a limitation not evident in the World Health Organisation Disability Assessment Schedule (WHODAS 2.0). This study aimed to cross-culturally adapt the WHODAS 2.0 and validate it in rural and urban Nigerian populations with CLBP. ⋯ Igbo-WHODAS appears psychometrically sound. Its research and clinical utility require further testing.
-
To study the efficacy and safety of fasinumab in moderate-to-severe, chronic low back pain (CLBP). ⋯ Fasinumab highest doses, but not lower dose, improved both CLBP pain and function. Most joint AEs occurred in pOA patients, consistent with earlier findings in symptomatic OA. Further study is needed of patients with CLBP with and without pOA to determine optimal benefit-risk.
-
Retrospective analysis of prospectively collected data. ⋯ 2.
-
This is a retrospective cohort study. ⋯ 4.